Presentation is loading. Please wait.

Presentation is loading. Please wait.

2005-11-10 M Nicklasson 1 The AstraZeneca Site in the Göteborg Region The Headquarter for Cardiovascular and Gastrointestinal Research Martin Nicklasson.

Similar presentations

Presentation on theme: "2005-11-10 M Nicklasson 1 The AstraZeneca Site in the Göteborg Region The Headquarter for Cardiovascular and Gastrointestinal Research Martin Nicklasson."— Presentation transcript:

1 2005-11-10 M Nicklasson 1 The AstraZeneca Site in the Göteborg Region The Headquarter for Cardiovascular and Gastrointestinal Research Martin Nicklasson Executive Vice President, AstraZeneca plc CEO & President, AstraZeneca AB

2 2005-11-10 M Nicklasson 2 AstraZeneca in Sweden Key figures Sales in Sweden2 billion SEK – percent of Group sales1.4% – including parallel import2.9 billion SEK Market share8.4% Rank in Swedish pharmaceutical marketNo. 2 Swedish export39 billion SEK Share of Swedish net export20% Swedish licensing income8 billion SEK No. of Swedish shareholders161,000 Share of Swedish ownership 22.7% (of total No. of shares)

3 2005-11-10 M Nicklasson 3 Mölndal

4 2005-11-10 M Nicklasson 4 R&D units Montreal Södertälje Boston CharnwoodAlderley Lund Mölndal Osaka Wilmington Reims Brisbane Bangalore

5 2005-11-10 M Nicklasson 5 AZ Cardiovascular Drug Discovery Research Areas at the Mölndal site Metabolism: Obesity Dyslipidemia Diabetes Atherosclerosis Thromboembolism Cardiology

6 2005-11-10 M Nicklasson 6 AZ Gastrointestinal Drug Discovery Research Areas at the Mölndal site Gastroesophageal Erosive Reflux Disease Functional Gastrointestinal Disorders Inflammatory Bowel Disease

7 2005-11-10 M Nicklasson 7 Key factors driving collaborations Access to broader basic knowledge as base for new projects or specific competence for key technologies Create networks to increase the recruitment base Access to unique expertise that cant or shouldnt be built in-house Facilitate establishment of high quality research groups within areas of long term strategic importance

8 2005-11-10 M Nicklasson 8 Elements of innovation in Drug Discovery at AstraZeneca 1. Presence in a global network of research sites on major continents within AstraZeneca 2.Effective in-house drug discovery and research informatics processes (knowledge transfer) 3. Mechanisms for learning (adoptation of best practices) 4. Network of important academic and biotechnology partners 5.Effective management of research at several sites and continents

9 2005-11-10 M Nicklasson 9 How important are the links to academic research in the Gothenburg region? Current AstraZeneca collaboration value to Gothenburg University amounts to a total of 7.34 m$ The relations with Academia have in the past contributed to significant discoveries (Losec®, Nexium®, Seloken®)

10 2005-11-10 M Nicklasson 10 Areas of collaboration in drug develop- ment – AstraZeneca and Gothenburg University Epidemiology – get to know the disease Mechanistical research – get to know how to test Proof of Principle for a new substance Large scale clinical trials – landmark studies with potential to change routine therapy General consultancy – expert advice at any stage of drug development

11 2005-11-10 M Nicklasson 11 Specific examples of collaboration Epidemiology Hypertension, myocardial infarction, heart failure Metabolic diseases – Diabetes – Obesity Acid secretion related to GI diseases

12 2005-11-10 M Nicklasson 12 Specific examples of collaboration Mechanistical research GI laboratory Metabolic laboratory Cardiovascular clinical physiology laboratory Arrhythmia laboratory Development of sophisticated techniques to measure treatment effects

13 2005-11-10 M Nicklasson 13 Specific examples of collaboration Large scale clinical trials Hypertension (e.g. HAPPHY, MAPHY, HOT) Heart failure (e.g. MERIT, CHARM) Myocardial infarction (GMT, MIAMI) Lipid disorders (CORONA) Thrombosis related disorders (METHRO) Acid secretion related GI disorders University scientists in Scientific Steering Committees. Results of studies which have (or will) shift treatment guidelines for the disease.

14 2005-11-10 M Nicklasson 14 Industry – academia collaboration Prerequisites – Scientists on both sides work together with Trust and Respect This requires – Same competence level – Personal chemistry OK – Genuine wish to collaborate N.B. – Need to be in frontline of research on a worldwide basis – Industry needs to seek collaboration with the best to be competitive

15 2005-11-10 M Nicklasson 15 Key factors for AstraZenecas continued presence in the region AstraZeneca captures biomedical innovations globally through its research presence at different continents. Critical for the locations in Gothenburg is: The proximity to and the ability of the local universities to develop world class basic bio- medical and chemical research The ability of the universities to educate high quality students To make clear and public statements in important ethical issues, such as: - Positive attitude and support to animal experimentation - Stem cell research Providing for excellent infrastructure facilities employment of scientists coming from abroad: - International schools of high quality The focus of the region to applied/translational research is for AstraZeneca of lesser importance

16 2005-11-10 M Nicklasson 16 Conclusions Academia and Biotech collaborations play and will play a very important part in AstraZeneca Academia research will always be a major source of innovation for pharma industry True partnership can only thrive when there is a natural interest between scientists Technology integration New Drug Project generation

Download ppt "2005-11-10 M Nicklasson 1 The AstraZeneca Site in the Göteborg Region The Headquarter for Cardiovascular and Gastrointestinal Research Martin Nicklasson."

Similar presentations

Ads by Google